Analysis of MET and RET Expression in Patients with Pancreatic Neuroendocrine Tumors Receiving Everolimus Abstract #2205

Introduction: Target therapy has improved the outcome of neuroendocrine tumors (NETs), but little is known about the strategies to overcome the acquired resistance. MET is considered one of the putative mechanisms of resistance. RET is also rearranged in some other endocrine tumors (like thyroid).
Aim(s): We performed an analysis of MET and RET expression in patients with metastatic pancreatic NETs receiving everolimus, before and after treatment, in order to investigate if MET or RET pathways activate as putative mechanisms of resistance to mTOR inhibitors. Other exploratory analyses have been performed.
Materials and methods: Liver biopsies from 10 patients before and after everolimus were collected. We used FISH for RET rearrangement and MET amplification and immunohistochemical (IHC) analysis for phospho-Met and PTEN protein expression. We addictionally speculate the role of PDL-1 IHC expression as putative predictive biomarker. A novel next generation sequencing (Oncomineā„¢ Solid Tumour DNA) was used to detect the mutation of 22 genes: EGFR, ERBB2, ERB4, MET, FGFR1, FGFR2, FGFR3, DDR2, ALK, KRAS, NRAS, PIK3CA, BRAF, PTEN, MAP2K1, AKT1, TP53, STK11, CTNNB1, SMAD4, FBXW7, NOTHC1.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD Chiara Alessandra Cella
Keywords: Everolimus, MET, RET

To read results and conclusion, please login ...

Further abstracts you may be interested in

#513 Correlation Between mTOR Pathway and Clinical Outcomes in Patients with Well-Differentiated Neuroendocrine Tumors Treated with Everolimus
Introduction: Everolimus has been studied in preclinical and clinical settings, showing it to be active and effective. Tumors exhibiting the constitutively activated phosphatidylinositol-3-kinase-AKT-mTOR (PI3K/AKT/mTOR) pathway, are potentially susceptible to mTOR inhibitors. Even though Everolimus is both an antiproliferative and anti-angiogenic drug, we do not know the possible prognostic or predictive role of p-mTOR pathway.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Francesca Spada
Authors: Spada F, Pisa E, Lorizzo K, Barberis M, ...
Keywords: mTOR
#2829 Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Multinational Study on Risk Factors and Outcomes
Introduction: The incidence and risk factors for everolimus-induced pneumonitis (EiP) have been poorly studied in patients (pts) with neuroendocrine neoplasms (NEN) outside of clinical trials.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD Rodrigo G Taboada
#1110 Chemotherapy with Capecitabine plus Temozolomide (CAP-TEM) in Patients with Advanced Neuroendocrine Neoplasms (NENs): An Italian Multicenter Retrospective Analysis
Introduction: A combination of capecitabine (CAP) and temozolomide (TEM) has been successfully used as first-line treatment in pancreatic neuroendocrine neoplasms (pNENs).
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: MD Francesca Spada
Keywords: NEN, NET, chemotherapy
#1421 Oxaliplatin-based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors
Introduction: The role of chemotherapy in low/intermediate grade neuroendocrine tumors (NETs) is still debated.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD Francesca Spada
Keywords: Oxaliplatin, NETs
#1642 Angiogenic Circulating Biomarkers in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus
Introduction: More than 10% of patient treated with Everolimus develop early onset of resistance. The lacking of adequate predictive factors in the targeted hera makes challenging the early identification of non-responders patients.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD Chiara Alessandra Cella
Authors: Cella C A, Spada F, Labanca V, Radice D, ...